menu
    • menu
    [{"orgOrder":0,"company":"Centessa Pharmaceuticals","sponsor":"General Atlantic","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Series A Financing","leadProduct":"Lixivaptan","moa":"V2R","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Centessa Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Centessa Pharmaceuticals \/ General Atlantic","highestDevelopmentStatusID":"10","companyTruncated":"Centessa Pharmaceuticals \/ General Atlantic"},{"orgOrder":0,"company":"Centessa Pharmaceuticals","sponsor":"Morgan Stanley","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Public Offering","leadProduct":"Lixivaptan","moa":"V2R","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Centessa Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Centessa Pharmaceuticals \/ Morgan Stanley","highestDevelopmentStatusID":"10","companyTruncated":"Centessa Pharmaceuticals \/ Morgan Stanley"},{"orgOrder":0,"company":"Centessa Pharmaceuticals","sponsor":"Oberland Capital Management","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2021","type":"Agreement","leadProduct":"Serpinpc","moa":"Protein C","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Centessa Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Centessa Pharmaceuticals \/ Oberland Capital Management","highestDevelopmentStatusID":"7","companyTruncated":"Centessa Pharmaceuticals \/ Oberland Capital Management"},{"orgOrder":0,"company":"Centessa Pharmaceuticals","sponsor":"Centessa Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Sleep","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Merger","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Sleep","graph2":"Preclinical","graph3":"Centessa Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Oral","sponsorNew":"Centessa Pharmaceuticals \/ Centessa Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"Centessa Pharmaceuticals \/ Centessa Pharmaceuticals"},{"orgOrder":0,"company":"Centessa Pharmaceuticals","sponsor":"Goldman Sachs","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2024","type":"Public Offering","leadProduct":"Serpinpc","moa":"APC receptor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Centessa Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Centessa Pharmaceuticals \/ Goldman Sachs","highestDevelopmentStatusID":"10","companyTruncated":"Centessa Pharmaceuticals \/ Goldman Sachs"},{"orgOrder":0,"company":"Centessa Pharmaceuticals","sponsor":"Goldman Sachs & Co","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2024","type":"Public Offering","leadProduct":"Serpinpc","moa":"APC receptor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Centessa Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Centessa Pharmaceuticals \/ Goldman Sachs & Co","highestDevelopmentStatusID":"10","companyTruncated":"Centessa Pharmaceuticals \/ Goldman Sachs & Co"},{"orgOrder":0,"company":"Centessa Pharmaceuticals","sponsor":"AnaptysBio","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Large Molecule","year":"2023","type":"Licensing Agreement","leadProduct":"CBS004","moa":"Undisclosed","graph1":"Immunology","graph2":"IND Enabling","graph3":"Centessa Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Centessa Pharmaceuticals \/ AnaptysBio","highestDevelopmentStatusID":"5","companyTruncated":"Centessa Pharmaceuticals \/ AnaptysBio"},{"orgOrder":0,"company":"Centessa Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"ZF874","moa":"A1AT gene","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Centessa Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Centessa Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Centessa Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Centessa Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Lixivaptan","moa":"V2R","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Centessa Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Centessa Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Centessa Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Centessa Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"LB101","moa":"PD-L1","graph1":"Oncology","graph2":"IND Enabling","graph3":"Centessa Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Centessa Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Centessa Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Centessa Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"ORX750","moa":"Undisclosed","graph1":"Sleep","graph2":"Phase I","graph3":"Centessa Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Oral","sponsorNew":"Centessa Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Centessa Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Centessa Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"ORX750","moa":"Undisclosed","graph1":"Sleep","graph2":"Phase I","graph3":"Centessa Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Oral","sponsorNew":"Centessa Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Centessa Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Centessa Pharmaceuticals","sponsor":"Sosei Group Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"ORX750","moa":"Undisclosed","graph1":"Sleep","graph2":"Phase I","graph3":"Centessa Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Oral","sponsorNew":"Centessa Pharmaceuticals \/ Sosei Group Corporation","highestDevelopmentStatusID":"6","companyTruncated":"Centessa Pharmaceuticals \/ Sosei Group Corporation"},{"orgOrder":0,"company":"Centessa Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"LB101","moa":"PD-L1","graph1":"Oncology","graph2":"IND Enabling","graph3":"Centessa Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Centessa Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Centessa Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Centessa Pharmaceuticals","sponsor":"ApcinteX","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Serpinpc","moa":"APC receptor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Centessa Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Centessa Pharmaceuticals \/ ApcinteX","highestDevelopmentStatusID":"10","companyTruncated":"Centessa Pharmaceuticals \/ ApcinteX"},{"orgOrder":0,"company":"Centessa Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Serpinpc","moa":"APC receptor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Centessa Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Centessa Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Centessa Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Centessa Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Serpinpc","moa":"Protein C","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Centessa Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Centessa Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Centessa Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Centessa Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Serpinpc","moa":"Protein C","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Centessa Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Centessa Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Centessa Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Centessa Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"LB101","moa":"PD-L1","graph1":"Oncology","graph2":"IND Enabling","graph3":"Centessa Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Centessa Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Centessa Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Centessa Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Lixivaptan","moa":"V2R","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Centessa Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Centessa Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Centessa Pharmaceuticals \/ Inapplicable"}]

    Find Clinical Drug Pipeline Developments & Deals by Centessa Pharmaceuticals

    Menu

    Centessa Pharmaceuticals

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Centessa Pharmaceuticals

                            U.S.A arrow
                            Peptide-Based Therapeutics Summit
                            Not Confirmed

                            Centessa Pharmaceuticals

                            U.S.A arrow
                            Peptide-Based Therapeutics Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Serpinpc

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase III

                            Sponsor : Goldman Sachs & Co

                            Deal Size : $225.0 million

                            Deal Type : Public Offering

                            DEALS_DEV arrow-down

                            Centessa Pharmaceuticals Prices Upsized $225M Public Offering of ADS

                            Details : The net proceeds will be used to fund the company's lead product to advance the clinical development of SerpinPC, a stage product invested in treating Hemophilia B.

                            Product Name : Serpinpc

                            Product Type : Protein

                            Upfront Cash : Undisclosed

                            December 09, 2024

                            Lead Product(s) : Serpinpc

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase III

                            Sponsor : Goldman Sachs & Co

                            Deal Size : $225.0 million

                            Deal Type : Public Offering

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Centessa Pharmaceuticals

                            U.S.A arrow
                            Peptide-Based Therapeutics Summit
                            Not Confirmed

                            Centessa Pharmaceuticals

                            U.S.A arrow
                            Peptide-Based Therapeutics Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ORX750

                            Therapeutic Area : Sleep

                            Study Phase : Phase I

                            Sponsor : Sosei Group Corporation

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Nxera Partner Centessa Reports Positive Ph 1 Data for ORX750 in Sleep-Deprived Volunteers

                            Details : ORX750 is an investigational, orally administered, highly potent and selective OX2R agonist designed to directly target the underlying pathophysiology of orexin neuron loss in narcolepsy type 1.

                            Product Name : ORX750

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            November 09, 2024

                            Lead Product(s) : ORX750

                            Therapeutic Area : Sleep

                            Highest Development Status : Phase I

                            Sponsor : Sosei Group Corporation

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Centessa Pharmaceuticals

                            U.S.A arrow
                            Peptide-Based Therapeutics Summit
                            Not Confirmed

                            Centessa Pharmaceuticals

                            U.S.A arrow
                            Peptide-Based Therapeutics Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Serpinpc

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase II

                            Sponsor : Goldman Sachs

                            Deal Size : $100.0 million

                            Deal Type : Public Offering

                            DEALS_DEV arrow-down

                            Centessa Pharmaceuticals Announces $100M Public Offering of American Depositary Shares

                            Details : The gross proceeds will be used to fund the clinical development of SerpinPC, which is being evaluated in the mid-stage clinical trial for the treatment of Hemophilia A and Hemophilia B.

                            Product Name : Serpinpc

                            Product Type : Protein

                            Upfront Cash : Undisclosed

                            April 23, 2024

                            Lead Product(s) : Serpinpc

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase II

                            Sponsor : Goldman Sachs

                            Deal Size : $100.0 million

                            Deal Type : Public Offering

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Centessa Pharmaceuticals

                            U.S.A arrow
                            Peptide-Based Therapeutics Summit
                            Not Confirmed

                            Centessa Pharmaceuticals

                            U.S.A arrow
                            Peptide-Based Therapeutics Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ORX750

                            Therapeutic Area : Sleep

                            Study Phase : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Centessa Announces Open IND for ORX750; Data Planned in Sleep-Deprived Volunteers

                            Details : ORX750 is an investigational OX2R agonist designed to target orexin neuron loss in narcolepsy type 1 (NT1), currently being developed as an oral therapy.

                            Product Name : ORX750

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            April 22, 2024

                            Lead Product(s) : ORX750

                            Therapeutic Area : Sleep

                            Highest Development Status : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Centessa Pharmaceuticals

                            U.S.A arrow
                            Peptide-Based Therapeutics Summit
                            Not Confirmed

                            Centessa Pharmaceuticals

                            U.S.A arrow
                            Peptide-Based Therapeutics Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CBS004

                            Therapeutic Area : Immunology

                            Study Phase : IND Enabling

                            Sponsor : AnaptysBio

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Anaptys Expands Immune Cell Modulator Pipeline with Exclusive License to BDCA2 Modulator Antibody Portfolio fr...

                            Details : Under the terms of the agreement, Anaptys will receive from Centessa an exclusive, global license for ANB101 (CBS004), a potentially best-in-class BDCA2 modulator antibody that targets pDCs and ANB102, an extended half-life BDCA2 modulator.

                            Product Name : ANB101

                            Product Type : Other Large Molecule

                            Upfront Cash : $10.0 million

                            November 27, 2023

                            Lead Product(s) : CBS004

                            Therapeutic Area : Immunology

                            Highest Development Status : IND Enabling

                            Sponsor : AnaptysBio

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Centessa Pharmaceuticals

                            U.S.A arrow
                            Peptide-Based Therapeutics Summit
                            Not Confirmed

                            Centessa Pharmaceuticals

                            U.S.A arrow
                            Peptide-Based Therapeutics Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ORX750

                            Therapeutic Area : Sleep

                            Study Phase : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Centessa Pharmaceuticals Announces Preclinical Data Supporting ORX750’s Potential as a Best-in-Class Oral OX...

                            Details : ORX750 is an investigational, orally administered, highly potent and selective orexin receptor 2 (OX2R) agonist designed to directly target the underlying pathophysiology of orexin neuron loss in narcolepsy type 1 (NT1).

                            Product Name : ORX750

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            October 25, 2023

                            Lead Product(s) : ORX750

                            Therapeutic Area : Sleep

                            Highest Development Status : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Centessa Pharmaceuticals

                            U.S.A arrow
                            Peptide-Based Therapeutics Summit
                            Not Confirmed

                            Centessa Pharmaceuticals

                            U.S.A arrow
                            Peptide-Based Therapeutics Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Serpinpc

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Centessa Pharmaceuticals to Present Additional Data from Open-Label Extension (OLE) of Phase 2a Study of Serpi...

                            Details : SerpinPC is designed to allow more thrombin to be generated by inhibiting activated protein C (APC) thus rebalancing coagulation in hemophilia A patients.

                            Product Name : Serpinpc

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            June 02, 2023

                            Lead Product(s) : Serpinpc

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Centessa Pharmaceuticals

                            U.S.A arrow
                            Peptide-Based Therapeutics Summit
                            Not Confirmed

                            Centessa Pharmaceuticals

                            U.S.A arrow
                            Peptide-Based Therapeutics Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : LB101

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Centessa Pharmaceuticals Announces FDA Clearance of IND Application for Phase 1/2a Clinical Trial of LB101, Fi...

                            Details : LB101 is a conditionally tetravalent PD-L1xCD47 LockBody bispecific monoclonal antibody which has two anti-CD47 domains blocked by two anti-PD-L1 domains, with proprietary human IgG-derived hinges linking the anti-CD47 and anti-PD-L1 domains.

                            Product Name : LB101

                            Product Type : Antibody

                            Upfront Cash : Inapplicable

                            January 26, 2023

                            Lead Product(s) : LB101

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Centessa Pharmaceuticals

                            U.S.A arrow
                            Peptide-Based Therapeutics Summit
                            Not Confirmed

                            Centessa Pharmaceuticals

                            U.S.A arrow
                            Peptide-Based Therapeutics Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : LB101

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Centessa Pharmaceuticals Announces Non-Human Primate Pharmacokinetic and Safety Data for LB101 (PD-L1xCD47) De...

                            Details : The non-clinical data demonstrate systemic delivery of high doses of LB101 without hematological toxicity in non-human primates, resulting in the potential to achieve an enhanced therapeutic index, increased anti-tumor activity, and enable treatment for ...

                            Product Name : LB101

                            Product Type : Antibody

                            Upfront Cash : Inapplicable

                            December 09, 2022

                            Lead Product(s) : LB101

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Centessa Pharmaceuticals

                            U.S.A arrow
                            Peptide-Based Therapeutics Summit
                            Not Confirmed

                            Centessa Pharmaceuticals

                            U.S.A arrow
                            Peptide-Based Therapeutics Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Serpinpc

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Centessa Pharmaceuticals Announces Additional 18-Months of Continued Treatment Data from Open-Label Extension ...

                            Details : SerpinPC, a biologic based on the serpin family of proteins, is designed to allow more thrombin to be generated by inhibiting activated protein C (APC) thus rebalancing coagulation in hemophilia patients.

                            Product Name : Serpinpc

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            October 12, 2022

                            Lead Product(s) : Serpinpc

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth